| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/16/2003 | WO2001060315A3 Method for the treatment or prevention of flavivirus infections using nucleoside analogues |
| 01/16/2003 | WO2001058954A9 Trade molecules and uses related thereto |
| 01/16/2003 | WO2001058946A9 Polynucleotides and polypeptides encoded thereby |
| 01/16/2003 | WO2001051049A9 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 01/16/2003 | US20030013881 Such as 4-((6-(3,5-difluoro-phenyl)-5-(S)-(3-dipropylcarb-amoyl-benzoyl-amino)-2-(R)-ethyl-4-(S)-hydroxy-hexanoylamino)-methyl)-cyclohexanecarboxylic acid for inhibiting secretase activity and cleavage of amyloid precursor protein |
| 01/16/2003 | US20030013866 Eukaryotic cells expressing the receptor |
| 01/16/2003 | US20030013855 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/16/2003 | US20030013853 Polypeptide for the treatment of gastrointestinal and neoplastic disorders |
| 01/16/2003 | US20030013850 Antiinflammatory agents |
| 01/16/2003 | US20030013848 Protein-tyrosine kinase genes |
| 01/16/2003 | US20030013847 Pyruvate derivatives |
| 01/16/2003 | US20030013846 Cytoprotective agents |
| 01/16/2003 | US20030013844 Multimerization of HIV-1 Vif protein as a therapeutic target |
| 01/16/2003 | US20030013759 Injection fatty acid, or salt thereof, into arteries |
| 01/16/2003 | US20030013725 Amino acid derivatives |
| 01/16/2003 | US20030013710 Sexual disorders |
| 01/16/2003 | US20030013700 Thrombin inhibitors |
| 01/16/2003 | US20030013677 Anticancer agents |
| 01/16/2003 | US20030013674 Gene therapy; in situ supplying of genes; nucleic acid complex |
| 01/16/2003 | US20030013673 Modulation activity by administering mutant polypeptide; controlling apoptosis |
| 01/16/2003 | US20030013669 Method of treating HIV infection and related secondary infections thereof |
| 01/16/2003 | US20030013668 Antiarthritic agents; inflammatory bowel disease; multiple sclerosis |
| 01/16/2003 | US20030013660 Dioxolane analogs for improved inter-cellular delivery |
| 01/16/2003 | US20030013659 Herpes virus |
| 01/16/2003 | US20030013658 Small peptides and methods for treatment of asthma and inflammation |
| 01/16/2003 | US20030013657 Reducing oxidation stresses; central nervous system disorders; antiinflammatory agents |
| 01/16/2003 | US20030013656 Reducing oxidation stresses; central nervous system disorders; antiinflammatory agents |
| 01/16/2003 | US20030013655 Compounds and methods for regulating cell adhesion |
| 01/16/2003 | US20030013654 Administering polypeptide |
| 01/16/2003 | US20030013653 Mixture with buffer and nonionic surfactant; storage stability |
| 01/16/2003 | US20030013652 Releasing moderators for inflammation |
| 01/16/2003 | US20030013651 Stimulation of osteogenesis using rank ligand fusion proteins |
| 01/16/2003 | US20030013649 Hybrid polypeptide |
| 01/16/2003 | US20030013648 Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
| 01/16/2003 | US20030013647 Selenocosmia huwena toxin and analgesic uses thereof |
| 01/16/2003 | US20030013646 Methods to stimulate insulin production by pancreatic beta-cells |
| 01/16/2003 | US20030013645 Central nervous system disorders; Alzheimer's disease; Parkinson's disease |
| 01/16/2003 | US20030013644 Complexing; therapy for genetic defects |
| 01/16/2003 | US20030013643 Prevention and treatment of streptococcal and staphylococcal infection |
| 01/16/2003 | US20030013642 Hemoglobin-haptoglobin complexes |
| 01/16/2003 | US20030013641 Complexing drug with diketopiperazine; washing; separation of impurities |
| 01/16/2003 | US20030013639 Sleep inducing antacid composition |
| 01/16/2003 | US20030013638 P27 prevents cellular migration |
| 01/16/2003 | US20030013637 Novel anti-autoimmune composition by inhibition of GRF action |
| 01/16/2003 | US20030013636 Prevent biosynthesis of galactoside |
| 01/16/2003 | US20030013634 Synthesis of small particles |
| 01/16/2003 | US20030013194 Prevention of membrane formation; obtain cell tissue, incubate with inhibitory collagen, monitor membrane formation |
| 01/16/2003 | US20030013191 Transgenic cells for use in human therapeutics and diagnostics |
| 01/16/2003 | US20030013179 Enzymatic polypeptide for use in the treatment of lysosomal storage disorders |
| 01/16/2003 | US20030013171 Nucleotide sequences coding polypeptide for use in treatment or prevention of immune system disorders |
| 01/16/2003 | US20030013170 Inhibitors of receptor activator of NF-kappaB and uses thereof |
| 01/16/2003 | US20030013169 Transcription factor E2F DNA-binding domain inhibitor peptides and their use |
| 01/16/2003 | US20030013155 Polypeptide for use in human therapeutics and diagnostics |
| 01/16/2003 | US20030013153 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/16/2003 | US20030013152 Nucleotide sequences coding polypeptide for use in human therapeutics |
| 01/16/2003 | US20030013151 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 01/16/2003 | US20030013095 Nuclcic acid enzyme for use in the prevention and treatment of infections and cancer |
| 01/16/2003 | US20030013082 Evaluation of effectiveness of herbal medicines in the treatment and prevention of viral infections; obtain cells, incubate with viricide, monitor viral gene expression, decrease in viral gene expression indicates viricides |
| 01/16/2003 | US20030013077 Binding to monoclonal antibodies; detection of Kaposi's sarcoma |
| 01/16/2003 | US20030013075 Diagnosing tumors in animal cells; obtain cells, detect expression of cancer marker gene, amplified concentration of marker gene expression indicates cancer |
| 01/16/2003 | US20030012825 Metallized molecule therapies |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012818 Bioactive molecule that is a non-glycosylated member of the cystine knot growth factor superfamily is physically entrapped in the polymeric matrix. |
| 01/16/2003 | US20030012817 Modified amino acids and derivatives can form non-covalent mixtures with active biological agents and in an alternate embodiment can releasably carry active agents. Modified amino acids can also form drug containing microspheres. |
| 01/16/2003 | US20030012812 Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| 01/16/2003 | US20030012795 Treating peripheral resistance in a mammal; modulating the immune response in a mammal |
| 01/16/2003 | US20030012794 Kits comprising heat shock protein-antigenic molecule complexes |
| 01/16/2003 | US20030012793 Purified complex of heat shock protein noncovalently bound to a molecule. |
| 01/16/2003 | US20030012792 Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| 01/16/2003 | US20030012790 Especially bispecific molecules comprising an IFN- gamma inhibitor and a further specificity to a target involved in the initiation or development of IBD, including ulcerative colitis and Crohn's disease. |
| 01/16/2003 | US20030012789 Conjugate of an antigen and a FcRn binding partner, wherein the antigen is characteristic of a tumor, and a pharmaceutically acceptable carrier |
| 01/16/2003 | US20030012788 Determining activation of various molecules, such as JAK-1, Tyk2, to identify molecules which mediate this interaction by measuring the activity of one or more of the molecules in the pathway to identify agonists and antagonists. |
| 01/16/2003 | US20030012787 Especially for ulcerative colitis and Crohn's disease. |
| 01/16/2003 | US20030012785 Intracellular drug delivery into an interleukin-2 receptor-bearing cell includes a chemical agent and a copy of an interleukin-2-receptor binding and endocytosis-inducing ligand bound to a water soluble polymer |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012782 Method and composition for altering a T cell mediated pathology |
| 01/16/2003 | US20030012778 Reversibly inactivated acidified plasmin |
| 01/16/2003 | US20030012776 A nucleic acid sequence which encodes RIAZ protein; abolishing drug resistance in cancer cells; drug development assay; diagnosing and treating cancer; gene therapy; prediction of chemosensitivity in cancer patients |
| 01/16/2003 | US20030012773 Diaper dermatitis preventative medication and a method for making and using same |
| 01/16/2003 | US20030012770 Recombinant p53 adenovirus methods and compositions |
| 01/16/2003 | US20030012768 Connective tissue growth factor-2 |
| 01/16/2003 | US20030012767 Tissue-specific taanscriptional regulatory sequence operably linked to the coding region of a gene that is essential for replication of said vector. |
| 01/16/2003 | US20030012766 Orally-administered interferon-tau compositions and methods |
| 01/16/2003 | US20030012762 Methods for treatment of human skin damaged by laser treatment or chemical peelings and compositions useful in such methods |
| 01/16/2003 | US20030012741 Process for the preparation of micronised collagen, and its therapeutic applications |
| 01/16/2003 | US20030012739 Containing rosiglitazone maleate and a fluid carrier. |
| 01/16/2003 | US20030010715 Use of cationic exchange chromatography on solid matrix carried out at basic pH |
| 01/16/2003 | CA2490386A1 Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist |
| 01/16/2003 | CA2455490A1 Delivery of dsrna to arthropods |
| 01/16/2003 | CA2453173A1 Mycobacterial antigens expressed during latency |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2453062A1 Group b streptococcus bvh-a5 antigens and corresponding dna fragments |
| 01/16/2003 | CA2453042A1 Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells |
| 01/16/2003 | CA2452980A1 Methods of administering vectors to synaptically connected neurons |
| 01/16/2003 | CA2452874A1 Oral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | CA2452872A1 Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 01/16/2003 | CA2452835A1 Aromatic sulfenates for type i phototherapy |
| 01/16/2003 | CA2452628A1 Methylation of histone h4 at arginine 3 |
| 01/16/2003 | CA2452592A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | CA2452578A1 Ephrin and eph receptor mediated immune modulation |